KEGG   DRUG: Sitagliptin and ipragliflozin
Entry
D11064            Mixture   Drug                                   
Name
Sitagliptin and ipragliflozin;
Sujanu (TN)
Component
(Sitagliptin phosphate [DR:D06645] | Sitagliptin [DR:D08516] | Sitagliptin phosphate [DR:D12294]), (Ipragliflozin [DR:D10196] | Ipragliflozin L-proline [DR:D10200])
Class
Antidiabetic agent
 DG02044  Hypoglycemic agent
  DG03035  Combination of DPP-4 inhibitor and SGLT2 inhibitor
Metabolizing enzyme substrate
 DG02924  UGT substrate
  DG03190  UGT2B7 substrate
Remark
Therapeutic category: 3969
Product: D11064<JP>
Efficacy
Antidiabetic
Comment
Ipragliflozin is primarily metabolized by UGT2B7.
Metabolism
Enzyme: UGT2B7 [HSA:7364]
Interaction
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   396  Antidiabetic agents
    3969  Others
     D11064  Sitagliptin and ipragliflozin
Drug groups [BR:br08330]
 Antidiabetic agent
  DG02044  Hypoglycemic agent
   DG03035  Combination of DPP-4 inhibitor and SGLT2 inhibitor
    D11064  Sitagliptin and ipragliflozin
 Metabolizing enzyme substrate
  DG02924  UGT substrate
   DG03190  UGT2B7 substrate
    D11064  Sitagliptin and ipragliflozin
Drug classes [BR:br08332]
 Antidiabetic agent
  DG02044  Hypoglycemic agent
   D11064  Sitagliptin and ipragliflozin
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D11064
Other DBs
PubChem: 375581011
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system